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Summary
 
The majority of T cell responses are restricted to peptide antigens bound by polymorphic ma-
jor histocompatibility complex (MHC) molecules. However, peptide antigens can be presented
to T cells by murine non-MHC–encoded CD1d (mCD1) molecules, and human T cell lines
specific for nonpeptide antigens presented on CD1 isoforms have been identified. It is shown
here that antigen-specific, mCD1-restricted lymphocytes can be generated in vivo by immu-
nizing mice with a combination of plasmids encoding chicken ovalbumin, murine CD1d, and
costimulatory molecules. Splenocytes from immunized mice have CD1d-restricted, MHC-
unrestricted, ovalbumin-specific cytolytic activity that can be inhibited by anti-CD1 antibodies
as well as a competing CD1-binding peptide. These results suggest a physiologic role for mu-
rine CD1d to present exogenous protein antigens.
 
C
 
lassically, MHC class I or class II molecules are re-
sponsible for presenting peptide antigens to T cells.
However, in both humans and mice, the non-MHC–
encoded CD1 family of cell surface proteins has been im-
plicated to also have an antigen-presenting function (1, 2).
Although MHC class I molecules mediate recognition of
nonself or infected tissues by the immune system, the func-
tion of CD1 molecules is still unclear. Unlike the MHC
proteins, CD1 molecules are nonpolymorphic and have
five isoforms: CD1a, -b, -c, -d, and -e (3). The isoforms
are conserved in several mammalian species (4) and have
been divided into two groups based on the sequences of
their external domains (5). CD1a, -b, -c, and -e comprise
group 1, while group 2 contains CD1d. Although all five
isoforms are found in humans, only the group 2 isoforms
are conserved from rodents to humans.
CD1 molecules share some characteristics with both
MHC class I and MHC class II ligands. CD1 proteins bear
some resemblance to the classical MHC class I proteins
both in overall sequence homology, especially in the 
 
a
 
3
domain, and by their usual association with 
 
b
 
2
 
-microglob-
ulin (
 
b
 
2m; references 5 and 6). However, unlike MHC
class I molecules, CD1 proteins have been reported to be
expressed without 
 
b
 
2m (7) and do not require the trans-
porter proteins associated with antigen processing (TAP)
for stable expression (8–10). The mechanism for antigen
processing for CD1 is more similar to that of MHC class II
than class I (11–13). Like MHC class II, human CD1b is
localized to endocytic compartments, including the special-
ized endosomes where MHC class II proteins are believed
to bind endocytosed antigens (14–17). The non-MHC–
encoded CD1 family of nonpolymorphic glycoproteins is,
therefore, similar to, yet distinct from, other antigen-pre-
senting molecules in its similarity to MHC class I by se-
quence, structural homology, and association with 
 
b
 
2m, as
well as its similarity to MHC class II by its cellular localiza-
tion and dependence on the endosomal compartment for
presentation of exogenous antigens.
Unlike classical MHC, CD1 can present nonpeptide
ligands such as mycolic acid (18), lipoarabinomannan (19),
and mycobacterial lipid antigens (20) to 
 
ab
 
 T cell recep-
tor–bearing lymphocytes. The presentation of foreign non-
peptide antigens by CD1
 
 
 
has been demonstrated for the
human CD1b and CD1c isoforms from which human
CD1d and its related murine isoforms are divergent (5).
Castaño et al. (2) have reported that murine non-MHC–
encoded CD1d (mCD1) can bind long peptides with hy-
drophobic and bulky amino acids. Immunization of mice
with CD1-transfected cells preincubated with peptide gen-
erated, CD1-restricted, peptide-specific CTL. These data
suggest that mCD1 may have a antigen-presenting function
by binding peptides with hydrophobic residues (2).
Murine autoreactive, CD1-restricted T cells have been
identified in unimmunized mice (21, 22). To test the bio-
logical significance of mCD1 presentation of foreign pro-
tein antigens, we generated an antigen-specific, CD1-
restricted response by plasmid DNA immunization. This
immunization protocol raised a CD1-restricted, ovalbu-
min-specific CTL response, demonstrating that protein an-
tigen is recognized in the context of mCD1 and elicits a
  
434
 
Antigen-specific, CD1-restricted CTL Response
 
cellular immune response in vivo. Lysis by these cytotoxic
lymphocytes are antigen and CD1 dependent, can be par-
tially abrogated by anti-CD1 antibodies, and are competi-
tively inhibited by an established CD1-binding peptide.
Furthermore, these CTLs lyse allogeneic targets in an anti-
gen-specific manner.
 
Materials and Methods
 
Mice.
 
C57BL/6 mice were purchased from The Jackson Lab-
oratories (Bar Harbor, ME) and maintained under standard con-
ditions in the University of California, San Diego Animal Facility
accredited by the American Association of Laboratory Care. Mice
of either sex were used at 2–4 mo of age. 
 
Preparation of Plasmid DNA.
 
The plasmid pACB-CD1 was
constructed by subcloning the BamHI–XhoI fragment from the
pBluescript vector encoding murine CD1D1 (reference 6; pro-
vided by S. Balk, Beth Israel Hospital, Boston, MA) into the
BamHI–SalI site of the pACB vector (23). The nCMVOVA,
nCMVB7-1, and nCMVB7-2 plasmids have been previously de-
scribed (24). DNA was prepared using maxiprep kits (Qiagen
Inc., Chatsworth, CA), with the modification of adding 0.1 vol
10% Triton X-114 (Sigma Chemical Co., St. Louis, MO) to the
clarified bacterial lysate before applying it to the column in the
kit. Before injection, the residual endotoxin level was quantified
using a limulus extract clot assay (Associates of Cape Cod, Woods
Hole, MA). Plasmid DNA with a level of 
 
,
 
5 ng endotoxin/mg
DNA was resuspended in sterile isotonic saline solution before
injection.
 
Immunizations.
 
Mice were immunized once a week for 2 wk.
Plasmids were injected intradermally in the tail base with 50 
 
m
 
g
of each plasmid indicated in 50 
 
m
 
l normal saline using a 25-gauge
needle.
 
Cytotoxic T Lymphocyte Assay.
 
Mice were killed and their
spleens were removed and teased apart in RPMI 1640 media
(BioWhittaker Inc., Walkersville, MD) supplemented with 2%
fetal bovine serum (FBS). In 24-well plates (Costar Corp., Cam-
bridge, MA) 7 
 
3
 
 10
 
6
 
 responders were incubated with 1 
 
3
 
 10
 
6
 
mitomycin C–treated stimulator cells in the presence of 50 IU/ml
recombinant human IL-2. The culture media was RPMI 1640
supplemented with 10% heat-inactivated FBS, 2 mM glutamine,
50 
 
m
 
M 2
 
b
 
-mercaptoethanol, and 1% penicillin and streptomycin.
Figure 1. Recognition of ovalbumin by CD1d1-restricted CTL. Three
mice per group were immunized with 50 mg of each plasmid at days 0
and 7. 2 wk after the first injection, mice were killed and restimulated in
vitro with CD1d1-transfected EL4 cells pulsed with ovalbumin protein
for 5 d in the presence of 50 IU rIL-2. The specificity of the resulting
pooled CTL was determined by measuring the lysis of CD1d1-transfected
RMAS cells incubated with ovalbumin in triplicate. (A) Immunizing
mice with a combination of plasmids enhances the CD1-restricted CTL
response. Mice were immunized with plasmids encoding ovalbumin,
mCD1d1, and B7.1 (diamonds); ovalbumin, mCD1d1, and B7.2 (crosses);
ovalbumin (circles); ovalbumin and mCD1d1 (squares); or mCD1d1 (trian-
gles). The values plotted are average protein-specific lysis 2 background
lysis. (B) CTL are specific for CD1d1 and ovalbumin. The splenocytes
from the three mice injected with plasmids encoding ovalbumin,
mCD1d1, and B7.1 were tested for their ability to lyse CD1-transfected
RMAS cells pulsed with ovalbumin (triangles), CD1-transfected RMAS
(squares), or RMAS cells pulsed with ovalbumin (circles) in triplicate. The
values plotted represent the average lysis for three mice. These experi-
ments were repeated twice.
Figure 2. Antibody inhibition of CD1-restricted CTL lysis. Four
C57BL/6 mice were immunized with plasmids encoding OVA,
mCD1d1, and B7.1 as in Fig. 1. Spleens were harvested after 2 wk and
restimulated in vitro for 5 d with CD1d1 transfected RMAS cells pulsed
with ovalbumin protein for 5 d with rIL-2. The splenocytes were pooled
and assayed for CTL activity in duplicate. The percentage of maximum
lysis relative to the value in the presence of targets and antigen alone 6
SEM is shown. This experiment was repeated five times.
Figure 3. Peptide inhibition of ovalbumin-specific, CD1-restricted
CTL lysis. T cell lines from mice injected with plasmids encoding OVA,
mCD1d1, and B7.1 were assayed for cytolytic activity. CD11 RMAS tar-
gets incubated with effector cells in triplicate wells were either unpulsed,
pulsed for 2 h with 4 mg/ml of p99, pulsed with 200 mg/ml of ovalbumin
protein for 1 h, washed, and then pulsed with 12 mg/ml of p99 for 1 h, or
pulsed with ovalbumin protein only. The percentage of lysis 6 SEM is
shown at an E/T ratio of 30:1. This experiment was repeated twice. 
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The stimulator cells, EL4-CD1 or RMAS-CD1, were stably
transfected with a pCDNA3 vector expressing murine CD1d1
(pCDNA3 CD1D1). These transfectants were incubated with
40–200 
 
m
 
g/ml ovalbumin protein (Sigma Chemical Co.) for 1 h
at 37
 
8
 
C and 5% CO
 
2 
 
and then treated with mitomycin C (Sigma
Chemical Co.) 50 
 
m
 
g/ml shaking for 30 min at 37
 
8
 
C. After 5 d,
the restimulated cells were harvested and separated from dead
cells on a lympholyte M gradient (Accurate Chemical and Scien-
tific Corp., Westbury, NY). In 96-well, round-bottom plates,
target cells were incubated in 200-
 
m
 
l volumes with restimulated
T cells at titrated E/T ratios for 4 h. The assay medium used was
phenol red–free RPMI 1640 supplemented with 2% BSA, 2 mM
glutamine, and 1% penicillin and streptomycin. The target cells
used were peptide transporter–deficient RMAS cells or RMAS
cells stably transfected with pCDNA3 CD1D1. Targets were
pulsed with 40–200 
 
m
 
g/ml ovalbumin protein at 37
 
8
 
C and 5%
CO
 
2
 
 for 1 h and then washed three times. 50 
 
m
 
l per well of the
supernatant was then transferred to 96-well plates and lysis was as-
sessed by measuring lactate dehydrogenase release using the Cyto-
tox 96 assay kit (Promega Corp., Madison, WI). Controls were
included on each plate for spontaneous LDH release from target
and effector cells. Percent lysis was calculated according to manu-
facturer’s instructions using the formula: [(test release 
 
2
 
 sponta-
neous release)/(maximum release 
 
2
 
 spontaneous release)] 
 
3
 
100%.
 
Peptide and Antibodies.
 
The p99 peptide, YEHDFHHIREW-
GNHWKNFLAVM, that has been reported to bind murine CD1d1
(2) was purchased from PeptidoGenic Research and Company
(Livermore, CA) HPLC purified. Antibodies used were anti-K
 
b
 
and D
 
b
 
, 20-8-4S (American Type Culture Collection [ATCC],
Rockville, MD), anti-CD1, 1B1 (PharMingen, San Diego, CA)
or 1H1 (PharMingen) or 3C11 (generously provided by S. Balk),
anti-CD8, 3.155 (ATCC), anti-CD4, YTS177, and anti-Fas ligand,
K-10 (PharMingen). All antibodies were used at 10 
 
m
 
g/ml with
the exception of 3C11 ascites used at a dilution of 1:50, 3.155 as-
cites used at a dilution of 1:300 and YTS177 ascites used at a dilu-
tion of 1:20. The antibodies 20-8-4S and 3.155 were capable of
blocking class I–restricted CD8
 
1
 
 T cell responses at these con-
centrations in pilot experiments.
 
Generation of T Cell Lines.
 
C57BL/6 mice were immunized
with plasmids encoding OVA, mCD1d1, and B7.1 twice. Sple-
nocytes were harvested 2 wk after the first injection and restimu-
lated in vitro for 6 d with CD1-transfected RMAS cells pulsed
with ovalbumin protein in IMDM (BioWhittaker) supplemented
with 10% Con A supernatant, 10% heat-inactivated FBS, 2 mM
glutamine, 50 
 
m
 
M 2
 
b
 
-mercaptoethanol, and 1% penicillin and
streptomycin. The cultured splenocytes were restimulated weekly
in 24-well plates with 10
 
5
 
 each of mitomycin C–treated, thiogly-
collate-activated syngeneic peritoneal macrophages and CD1-
transfected RMAS cells pulsed with ovalbumin protein in Con
A–supplemented complete IMDM.
 
Results and Discussion
 
Generation of Ovalbumin-specific, CD1-restricted CTL.
 
Intra-
dermal administration of plasmid DNA induces antigen-spe-
cific immune responses (25) and allows for the ectopic ex-
pression of membrane-bound molecules such as CD1 and
costimulators, as well as the expression of the antigen, chicken
ovalbumin. Therefore, we chose this approach to test the
biological significance of CD1 presentation of peptide from
whole protein antigens. CD1 expression has been detected
on gastrointestinal epithelium, thymus, liver, and spleen (6,
26). As murine CD1 is not prevalent in the dermis, a coin-
jection strategy was used to ectopically express the antigen-
presenting molecule (CD1d1) as well as the antigen. Addi-
tionally, plasmids encoding costimulatory molecules B7.1
or B7.2 were included to provide the responsive T cell
with a nonspecific second signal in the same milieu as the
cognate signal (27–29). Chicken ovalbumin was selected as
the test antigen as it contains a peptide with the reported
mCD1-binding motif (2). In these experiments, antigen
loading of target cells was accomplished by incubating
them with whole protein, because as recent reports suggest,
CD1 antigen loading occurs through a TAP-independent
endocytic mechanism (11–13). The TAP independence of
CD1 antigen processing made TAP-deficient, CD1-trans-
fected RMAS cells the preferred target cells (9, 10).
Hence, C57BL/6 mice were immunized with different
combinations of plasmid DNA encoding mCD1D1 (pACB-
CD1), chicken ovalbumin (nCMV-OVA), and costimula-
tor molecules (nCMV-B7.1 or nCMV-B7.2) at weeks zero
and one. Mice were killed at week 2, and after in vitro re-
stimulation, their splenocytes were assayed for their ability
to lyse H-2
 
b
 
 CD1-transfected RMAS cells. Mice immu-
nized with a combination including B7.1-expressing plas-
mid repeatedly gave a higher specific lysis than mice immu-
nized with a B7.2-encoding plasmid (Fig. 1 
 
A
 
). The in
vivo requirement for adding a CD28 ligand is in contrast to
in vitro studies with CD1b- or CD1c-restricted human T
cell hybridomas that use a pathway of costimulation outside
the interaction between CD28 and its counterreceptors
(30).
 
CTL Activity Is Antigen and CD1 Dependent.
 
Splenocytes
from mice immunized with the combination of plasmids
encoding ovalbumin, mCD1d1, and B7.1 were able to lyse
Figure 4. Ovalbumin-specific,
CD1-restricted CTL lysis of
allogeneic targets. 10 C57BL/6
mice (H-2b) were immunized
with plasmids encoding OVA,
mCD1d1, and B7.1 (circles), and
four mice were immunized with
mCD1d1 and B7.1 (squares) on
days 0 and 10. 2 wk after the first
injection, mice were killed and
restimulated in vitro with
CD1d1-transfected RMAS cells
pulsed with ovalbumin protein
for 5 d in the presence of 50 IU/
ml rIL-2. CD11 RMAS or
CD11 P815 targets were incu-
bated in the presence or absence
of ovalbumin protein (100 mg/
ml) for 1 h and washed three
times before being plated with
effector cells in triplicate wells.
The specific lysis was determined
by measuring the lysis of CD11
RMAS cells pulsed with ovalbu-
min minus unpulsed transfectants (A) or CD11 P815 cells pulsed with
ovalbumin minus unpulsed transfectants (B). The values plotted represent
the average lysis 6 SEM. This experiment was repeated twice. 
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MHC class I–deficient, CD1
 
1
 
 RMAS transfectants pulsed
with ovalbumin more effectively than untransfected
RMAS cells pulsed with ovalbumin (Fig. 1 
 
B
 
). Although
RMAS cells have very low levels of detectable CD1 ex-
pression on their surface by cytofluorometric analysis, aug-
menting the level of surface CD1 by transfection resulted
in a threefold increase in cytotoxic lysis in the 4-h period of
the assays. To verify that the incubation with ovalbumin
did not spuriously result in MHC class I surface loading of
peptide that was resulting in CTL recognition, antigen pre-
sentation was inhibited with antibodies. An antibody di-
rected against MHC class I (H-2K 
 
b
 
/D 
 
b
 
) partially de-
creased lysis by 23%, whereas the anti-CD1 antibodies
inhibited lysis by 
 
z
 
45–60% (Fig. 2). None of the anti-CD1
antibodies were able to completely inhibit lysis at the con-
centrations used. In fact, the extent of inhibition varied be-
tween experiments, with the 1H1 antibody being the most
effective. This variation between the different anti-CD1
antibodies may reflect differences in their affinities for anti-
gen or may represent different epitopes seen by mixed pop-
ulations of T cells in each experiment.
To confirm that the CTL response was ovalbumin spe-
cific and the effector cells were not simply recognizing a
conformation of CD1d1 stabilized by binding a peptide,
we tested the CTL for lysis activity of CD1
 
1
 
 RMAS cells
pulsed with the p99 peptide previously described to bind
murine CD1d1 (reference 2; Fig 3). The lysis of targets
pulsed with p99 (16%) was not different from unpulsed tar-
gets (18%). Furthermore, p99 competitively inhibited lysis
of CD1
 
1
 
 RMAS cells pulsed with ovalbumin protein, de-
creasing lysis from 82 to 37%.
 
CTL Are Antigen Specific and MHC Unrestricted.
 
Given that
CD1 is nonpolymorphic, the same immunization protocol
that was effective in generating CD1-restricted CTL in H-2
 
b
 
mice should also generate CTL that recognize CD1 on
cells of another MHC haplotype. Splenocytes from
C57BL/6 (H-2
 
b
 
) mice immunized with plasmids encoding
mCD1D1 and B7.1 or mCD1D1, B7.1, and ovalbumin
were tested for CTL activity to CD1D1-transfected P815
targets pulsed in the presence or absence of ovalbumin pro-
tein. The background lysis of CD1D1-transfected P815 in
the absence of ovalbumin was 
 
z
 
45% at the highest E/T ra-
tio, suggesting a partial allogeneic response, which was sub-
tracted to give the percent antigen-specific lysis. However,
H-2
 
b
 
 mice immunized with the three plasmids were re-
peatedly able to mount a significant CTL response against
both CD1D1-transfected, ovalbumin-pulsed H-2
 
b
 
 RMAS
cells and H-2
 
d
 
 P815 cells (Figs. 4, 
 
A
 
 and 
 
B
 
), when com-
pared to the response in the negative control group.
 
CTL Effectors Are Predominantly CD8
 
1
 
 and Lysis Is Fas In-
dependent.
 
To further characterize the phenotype of the
CD1-restricted CTL, blocking antibodies to CD4 and
CD8 were used (Fig. 2). Anti-CD8 repeatedly blocked ly-
sis, whereas anti-CD4 blocked lysis less consistently. The
variation of inhibition between experiments by anti-CD4
implies a mixed effector population from the whole spleen
preparations. Recently, Stenger et al. (31) have identified
two mechanisms of CD1-restricted, cell-mediated cytotox-
icity to contribute to the outcome of infection with intra-
cellular pathogens. CD1-restricted T cells that are CD4
 
2
 
CD8
 
2
 
lysed targets through the Fas–Fas ligand pathway while
having no effect on intracellular bacterial survival, whereas
CD8
 
1
 
 effector cells used perforin and granzymes to kill the
bacteria as well as their host cell. In our studies, antibodies
against Fas ligand had no effect on the lysis of CD1-trans-
fected cells pulsed with ovalbumin (Fig. 2).
In summary, these studies demonstrate that normal mice
are able to generate ovalbumin-specific CTL restricted to
CD1 in vivo. The highly conserved nature of CD1 pro-
teins suggests that they may have evolved a specialized
function to present nonpeptidic ligands to T cells (1). The
crystal structure of CD1d1 reveals many differences from
classical MHC molecules (32), including a deep and highly
hydrophobic groove that would be structurally difficult to
bind peptides in the manner of MHC molecules (33).
However, there remains the possibility that CD1d may also
present hydrophobic peptides
 
 
 
that bind in a different con-
figuration as suggested by the CD1d peptide–binding motif
and synthetic peptide binding studies (2). The data pre-
sented here suggest that in addition to lipids and other non-
peptidic molecules, proteins can be recognized as antigens
in the context of CD1
 
 
 
in vivo to prime CTL that are anti-
gen specific.
CD1-reactive cells have been identified in mice, how-
ever, the physiological role of CD1 antigen presentation is
unknown. One population in particular, the CD4
 
1
 
 NK1
 
1
 
T cells, has been shown to make IL-4 (21, 34) in response
to CD1. Although MHC class II
 
8
 
 mice are relatively defi-
cient in CD4
 
1
 
 cells, they have been described to contain
greater numbers of CD4
 
1
 
 NK1
 
1
 
 T cells compared to wild-
type mice (22). In these mice, with the absence of MHC
II–restricted CD4
 
1
 
 T cells, CD4
 
1
 
 NK1
 
1 cells appear to be
important in providing help by serving as an early source of
IL-2 in the priming of CD81 CTL in the induction of re-
sistance to infection by the intracellular parasite, Toxoplasma
gondii (35). The physiologic relevance of CD1 presentation
of antigens remains unclear since T cells that recognize
these molecules have been described as having similar ef-
fector functions as MHC class I– and class II–restricted T
cells. Whether CD1-restricted T cells fulfill an ancillary,
regulatory, or completely independent role in the immune
system warrants further investigation.
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